Evidence map›Paper›PMID 22569534›Full record

ArticleJournal of virological methods2012

Purification of full-length VP22 from cells infected with HSV-1: A two-pronged approach for the solubilization and purification of viral proteins for use in biochemical studies.

Ebony J Dewberry, Eric Dunkerley, Carol Duffy

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ebony J DewberryDepartment of Biological Sciences, University of Alabama, 300 Hackberry Lane, Tuscaloosa, AL 35487, USA.
Eric Dunkerley
Carol Duffy
University of Alabama · US

Funding

The Role of VP22 in Protein Synthesis and mRNA Accumulation During HSV-1 InfectioR21AI083952 · NIAID · UNIVERSITY OF ALABAMA IN TUSCALOOSA · PI DUFFY, CAROL LYNN · 2009 to 2010
$389k
Howard Hughes Medical InstituteNIAID NIH HHS R21 AI083952NIAID NIH HHS R21 AI083952-01
6 · The paper itself

Abstract

VP22, encoded by the U(L)49 gene, is one of the most abundant proteins of the herpes simplex virus type 1 (HSV-1) tegument and has been shown to be important for virus replication and spread. However, the exact role(s) played by VP22 in the HSV-1 replication cycle have yet to be delineated. The lack of a procedure to purify full-length VP22 has limited molecular studies on VP22 function. A procedure was developed for the purification of soluble, full-length VP22 from cells infected with HSV-1. A recombinant virus encoding His-tagged VP22 was generated and found to express VP22 at levels comparable to the wild type virus upon infection of Vero cells. By experimenting with a wide variety of cell lysis buffer conditions, several buffers that promote the solubility of full-length VP22 were identified. Buffers that gave the highest levels of solubility were then used in immobilized metal ion affinity chromatography experiments to identify conditions that provided the greatest level of VP22 binding and recovery from cobalt and nickel affinity resins. Using this strategy soluble, full-length VP22 was purified from cells infected with HSV-1.

Indexed as

AnimalsBuffersChlorocebus aethiopsChromatography, AffinityCloning, MolecularHerpesvirus 1, HumanRecombinant Fusion ProteinsSolubilityVero CellsViral Structural ProteinsBuffersherpes simplex virus type 1 protein VP22Recombinant Fusion ProteinsViral Structural Proteins

Identifiers

PMID22569534
PMCPMC3390931
OpenAlexW2052967105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.